Psychedelic Therapy: A Primer for Primary Care Clinicians—3,4-Methylenedioxy-methamphetamine (MDMA)

1Centre for Eudaimonia and Human Flourishing, University of Oxford, Oxford, United Kingdom;

2Department of Psychiatry, University of Oxford, Oxford, United Kingdom;

3University of Nevada, Reno School of Medicine, Reno, NV;

4Department of Neurology, Carson Tahoe Health, Carson City, NV;

5Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA;

6University of Southern California, Keck School of Medicine, Los Angeles, CA;

7Department of Psychiatry & Behavioral Sciences, Stanford University, Palo Alto, CA;

8Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY;

9Teachers College, Columbia University, New York, NY;

10Fermata Health, Brooklyn, NY; and

11Acacia Clinics, Sunnyvale, CA.

*Address for correspondence: Kenneth Shinozuka, BA, Centre for Eudaimonia and Human Flourishing, 7 Stoke Place, Headington, Oxford OX3 9BX, United Kingdom. E-mail: [email protected]

The authors have no conflicts of interest to declare.

留言 (0)

沒有登入
gif